Axol Bioscience and Censo Biotechnologies announce merger
Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, today announced that the two companies have signed a merger agreement.
ERS Genomics and Setsuro Tech sign CRISPR/Cas9 licence agreement
Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models.
IONTAS and FairJourney Biologics enter antibody discovery agreement with Quell Therapeutics
Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimisation of fully human antibodies, have announced that they have entered into an agreement with Quell Therapeutics Limited regarding IONTAS / FJB’s proprietary libraries and technology platforms.
Nonacus introduces Whole Genome Sequencing service to support SARS-CoV-2 testing laboratories
Birmingham, UK: Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, today announced the commercial launch of a new service for Whole Genome Sequencing of SARS-CoV-2, developed to enable the UK government’s Test-To-Release scheme. Assay development for the new service was funded by a grant from Innovate UK, the UK’s innovation agency.
Avacta’s rapid antigen test is confirmed to detect SARS-CoV-2 new variants
Avacta’s AffiDX SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus.
Dotmatics announces licensing agreement for informatics software with Compugen
Bishop’s Stortford, UK, 3rd March 2021: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has entered a licensing agreement with Compugen, a clinical-stage drug discovery and development company focused on immuno-oncology. The multi-year agreement…
ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical
Licence to Nobel prize winning CRISPR technology supports internal research and development.
WuXi AppTec completes acquisition of OXGENE
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy…
ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development
DUBLIN, Ireland, 01 March 2021: ERS Genomics Limited (ERS), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Jon Kratochvil as Vice-President for Business Development & Licensing for North America.
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Seoul, Korea, 23 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc. (G+FLAS), a biotechnology company developing research tools and reagents associated with CRISPR technology, today announced a non-exclusive licence agreement…
Optibrium appoints Dr Rae Lawrence as Director of Software Development
Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Rae Lawrence as Director of Software Development. With the continued success of the Company’s portfolio of cheminformatics and AI-based drug discovery software, and the recent backing by Kester Capital, Optibrium has made the new appointment to drive its product development agenda. Rae will focus on…
Cell Guidance Systems’ nanoparticle cytokines enable use of macrophages to treat disease
Cell Guidance Systems Ltd, a specialist in the control, manipulation and monitoring of cells, both in vitro and in vivo, today announced its POlyhedrin Delivery System (PODS) technology has been shown to modulate macrophage secretion profiles with therapeutic potential. The results of this research are available as an unpublished preprint in bioRxiv1.
Avacta announces phase 1 Clinical Trial Authorisation (CTA) for AVA6000 approved by MHRA
Cambridge and Wetherby, 18 February 2021: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a phase I study of its lead pre|CISION™ pro-drug, AVA6000 pro-doxorubicin.
ERS Genomics and ZeClinics sign CRISPR/Cas9 licence agreement
Dublin, Ireland & Barcelona, Spain, 16 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analysing the safety, efficacy and biomedical relevance of new compounds, today…
Avacta announces results of initial evaluation of SARS-CoV-2 lateral flow antigen test with clinical samples
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK. These data show excellent performance of the test in identifying patients with an infectious viral load and no false positive results.
Optibrium raises investment to advance computer-aided drug discovery
Investment by Kester Capital will drive commercial growth and the development of new products to improve speed, efficiency, and productivity of the discovery process.
Avacta Group plc announces commercial partnership with Mologic
New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries.
FairJourney Biologics Group introduces Flow Eighteen38 for protein production and antibody characterization services
Porto, Portugal, 8th February 2021: FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterization data on antibody panels…
Avacta announces AffyXell $7.3 million Series A financing
Avacta’s next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding.
Metrion Biosciences and Sosei Heptares to explore structure-based drug discovery (SBDD) approaches to ion channels through strategic technology collaboration
Cambridge, UK and Tokyo, Japan, 01 February 2021– Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company and Sosei Group Corporation (“the Company”; TSE: 4565), the international biopharmaceutical group, announce they will apply Sosei Heptares’ world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new…
Avacta announces collaboration agreement with Bruker
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS™) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc.
Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range
Uppsala, Sweden...Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows. The new Gyrolab Bioaffy 4000, with a 4000 nL sample volume, is based on the proven design of Gyrolab Bioaffy 1000 CD,…
Dotmatics collaborates with HighRes Biosolutions to provide single software interface for lab digitalization
Bishop’s Stortford, UK, and Beverly, MA, 25 January 2021: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced a partnership with HighRes Biosolutions (HighRes), a company that designs and builds innovative robotic systems and laboratory devices.
Optibrium enhances compound design strategies in major upgrade to StarDrop software
Optibrium™, a developer of software for drug discovery, has announced the release of the newest version of StarDrop™, a comprehensive software platform for small molecule design, optimisation and data analysis. The new release, StarDrop 7.0, further extends the software’s compound design strategies, provides enhanced workflows, and seamlessly connects with Optibrium’s Cerella™ platform,…